![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
T Yasumori, L Chen, K Nagata, Y Yamazoe and R Kato
Department of Pharmacology, School of Medicine, Keio University, Tokyo, Japan.
Stereoselective involvement of hepatic cytochrome P450 in the metabolism of mephenytoin was investigated in vitro by using livers of five different experimental animal species and humans. The rates of microsomal 4'-hydroxylation were 2 to 6 times higher with the R- enantiomer than the S-enantiomer in rabbits, dogs and rats, whereas the rates of the 4'-hydroxylation in female mice were not different between R- and S-enantiomers. Preferential S-mephenytoin 4'-hydroxylation was observed in monkeys as similar to that in humans. The rates of microsomal mephenytoin N-demethylation were approximately 2 times higher with the R-enantiomer than the S-enantiomer in male rats and both sexes of dogs. Antibodies raised against CYP2C11 (anti-CYP2C) clearly inhibited microsomal 4'-hydroxylation of S-mephenytoin and N- demethylation of R-mephenytoin in rats, monkeys and humans. Antibodies raised against CYP3A2 (anti-CYP3A) clearly inhibited microsomal 4'- hydroxylation of R-mephenytoin, but marginally S-mephenytoin, in rats. Anti-CYP3A, however, showed no clear inhibition on microsomal 4'- hydroxylation and N-demethylation of both enantiomers in monkeys and humans, except for slight inhibition of R-mephenytoin 4'-hydroxylation in male monkeys. The results suggest that stereoselective involvement of rat CYP3A and scant involvement of human CYP3A in R-mephenytoin 4'- hydroxylation are major determinants of the species differences between rats and humans in stereoselective mephenytoin 4'-hydroxylation.
This article has been cited by other articles:
|
|
 |
|
  M. Mitsuda, M. Iwasaki, and S. Asahi Cynomolgus Monkey Cytochrome P450 2C43: cDNA Cloning, Heterologous Expression, Purification and Characterization. J. Biochem., May 1, 2006; 139(5): 865 - 872. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Yamamoto, N. Hagima, M. Nakamura, Y. Kohno, K. Nagata, and Y. Yamazoe Differences in Cytochrome P450 Forms Involved in the Metabolism of N,N-Dipropyl-2-[4-methoxy-3-(2-phenylethoxy)phenyl]ethylamine monohydrochloride (NE-100), a Novel Sigma Ligand, in Human Liver and Intestine Drug Metab. Dispos., January 1, 2003; 31(1): 60 - 66. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. K. Paulson, L. Engel, B. Reitz, S. Bolten, E. G. Burton, T. J. Maziasz, B. Yan, and G. L. Schoenhard Evidence for Polymorphism in the Canine Metabolism of the Cyclooxygenase 2 Inhibitor, Celecoxib Drug Metab. Dispos., October 1, 1999; 27(10): 1133 - 1142. [Abstract] [Full Text]
|
|
|
|
 |
|
 A. D. M. Kashuba, J. R. Dyer, L. M. Kramer, R. H. Raasch, J. J. Eron, and M. S. Cohen Antiretroviral-Drug Concentrations in Semen: Implications for Sexual Transmission of Human Immunodeficiency Virus Type 1 Antimicrob. Agents Chemother., August 1, 1999; 43(8): 1817 - 1826. [Full Text]
|
|
|
|
|
|
R. L. Voorman, S. M. Maio, M. J. Hauer, P. E. Sanders, N. A. Payne, and M. J. Ackland Metabolism of Delavirdine, a Human Immunodeficiency Virus Type-1 Reverse Transcriptase Inhibitor, by Microsomal Cytochrome P450 in Humans, Rats, and Other Species: Probable Involvement of CYP2D6 and CYP3A Drug Metab. Dispos., July 1, 1998; 26(7): 631 - 639. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. H. Lin and A. Y. H. Lu Role of Pharmacokinetics and Metabolism in Drug Discovery and Development Pharmacol. Rev., December 1, 1997; 49(4): 403 - 449. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Chauret, A. Gauthier, J. Martin, and D. A. Nicoll-Griffith In Vitro Comparison of Cytochrome P450-Mediated Metabolic Activities in Human, Dog, Cat, and Horse Drug Metab. Dispos., October 1, 1997; 25(10): 1130 - 1136. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
